Clarification of Media Reporting

 Clarification of Media Reporting

1.Date of occurrence of the event:2024/10/18
2.Company name:PharmaEssentia Corp.
3.Relationship with the Company (please enter "the company itself" or
  "subsidiaries"):the company itself
4.Reciprocal shareholding percentage:N/A
5.Name of the reporting media:
Economic Daily News
Column: C4
6.Content of the report:
On October 18th, 2024, the Economic Daily News reported:
"PharmaEssentia aims to double its revenue this year."
"PharmaEssentia stated that…Ropeg can be administered once every 2
 months…"
"PharmaEssentia Q4 revenue growth momentum will be stronger than the
 previous three quarters, with its annual revenue potentially doubling
 and aiming to reach the 10 billion NTD milestone."
7.Cause of occurrence:Clarification of reporting content
8.Countermeasures:
(1)Ropeginterferon alfa-2b (Ropeg) is recommended for subcutaneous
   injection once every 2 weeks.
(2)The Company did not provide any financial or business forecasts.
   The contents of reporting above were speculations by the press and
   institutional investors. For information related to the Company's
   finances and business please refer to the information disclosed in
   the "Market Observation Post System."
9.Any other matters that need to be specified:
It takes a considerable time and expense to develop a new drug. In
addition, the success of such development cannot be guaranteed.
Therefore, the investors will bear investment risk and should carefully
consider investment decisions.